tetano
Editor, Senior Moderator
J Med Econ
. 2021 Mar 24;1.
doi: 10.1080/13696998.2021.1908000. Online ahead of print.
Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany
Rui Cai[SUP] 1 [/SUP], Laetitia Gerlier[SUP] 2 [/SUP], Martin Eichner[SUP] 3 4 [/SUP], Markus Schwehm[SUP] 5 [/SUP], Sankarasubramanian Rajaram[SUP] 6 [/SUP], Joaquin Mould-Quevedo[SUP] 7 [/SUP], Mark Lamotte[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Standard influenza vaccines are produced using egg-based manufacturing methods. Through the process, the resulting egg-adapted viral strains may differ from the selected vaccine strain. Cell-derived influenza vaccine manufacturing prevents egg-adaptation of the antigen which can improve vaccine effectiveness. We evaluated the cost-effectiveness of quadrivalent cell-derived influenza vaccine (QIVc) versus an egg-based quadrivalent influenza vaccine (QIVe) in preventing seasonal influenza from German societal and payer perspectives.Methods: Adapted version of the individual-based dynamic 4Flu transmission model was combined with a decision-tree to calculate the impact of QIVc versus QIVe on influenza over 20 seasons in Germany. Egg-adaptation, resulting in lower effectiveness of QIVe versus QIVc towards the H3N2 influenza strain, is sourced from a US retrospective study and assumed in 100% (base case) or 55% (conservative scenario) of years. Influenza-related probabilities of outpatient visits, hospitalizations, productivity loss, and mortality, with associated (dis)utilities/costs, were extracted from literature. Costs and outcomes were discounted 3.0%/year.Results: Replacing QIVe with QIVc in subjects aged ?9 years can annually prevent 167,265 symptomatic cases, 51,114 outpatient visits, 2,091 hospitalizations, and 103 deaths in Germany. The annual number of quality-adjusted life-years (QALYs) increased by 1,628 and healthcare costs decreased by ?178M from societal perspective. From payer perspective, the incremental cost-effectiveness ratio was ?2,285 per QALY. Scenario analyses confirmed results robustness.Conclusions: The use of QIVc compared to QIVe, in the German Immunization Program, could significantly prevent outpatient visits and hospitalizations and would enable substantial savings from a societal perspective.
Keywords: C50; C51; C53; Cost-effectiveness; cell-derived; influenza; vaccination; vaccine effectiveness.
. 2021 Mar 24;1.
doi: 10.1080/13696998.2021.1908000. Online ahead of print.
Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany
Rui Cai[SUP] 1 [/SUP], Laetitia Gerlier[SUP] 2 [/SUP], Martin Eichner[SUP] 3 4 [/SUP], Markus Schwehm[SUP] 5 [/SUP], Sankarasubramanian Rajaram[SUP] 6 [/SUP], Joaquin Mould-Quevedo[SUP] 7 [/SUP], Mark Lamotte[SUP] 2 [/SUP]
Affiliations
- PMID: 33761803
- DOI: 10.1080/13696998.2021.1908000
Abstract
Background: Standard influenza vaccines are produced using egg-based manufacturing methods. Through the process, the resulting egg-adapted viral strains may differ from the selected vaccine strain. Cell-derived influenza vaccine manufacturing prevents egg-adaptation of the antigen which can improve vaccine effectiveness. We evaluated the cost-effectiveness of quadrivalent cell-derived influenza vaccine (QIVc) versus an egg-based quadrivalent influenza vaccine (QIVe) in preventing seasonal influenza from German societal and payer perspectives.Methods: Adapted version of the individual-based dynamic 4Flu transmission model was combined with a decision-tree to calculate the impact of QIVc versus QIVe on influenza over 20 seasons in Germany. Egg-adaptation, resulting in lower effectiveness of QIVe versus QIVc towards the H3N2 influenza strain, is sourced from a US retrospective study and assumed in 100% (base case) or 55% (conservative scenario) of years. Influenza-related probabilities of outpatient visits, hospitalizations, productivity loss, and mortality, with associated (dis)utilities/costs, were extracted from literature. Costs and outcomes were discounted 3.0%/year.Results: Replacing QIVe with QIVc in subjects aged ?9 years can annually prevent 167,265 symptomatic cases, 51,114 outpatient visits, 2,091 hospitalizations, and 103 deaths in Germany. The annual number of quality-adjusted life-years (QALYs) increased by 1,628 and healthcare costs decreased by ?178M from societal perspective. From payer perspective, the incremental cost-effectiveness ratio was ?2,285 per QALY. Scenario analyses confirmed results robustness.Conclusions: The use of QIVc compared to QIVe, in the German Immunization Program, could significantly prevent outpatient visits and hospitalizations and would enable substantial savings from a societal perspective.
Keywords: C50; C51; C53; Cost-effectiveness; cell-derived; influenza; vaccination; vaccine effectiveness.